Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomic Profiling of Diabetic Porcine Wound Healing Model Identifies Key Metabolic, Inflammatory, and Oxidative Stress Pathways.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2026
Same author

Evaluating the effects of aging on distribution and gene silencing activity of lipid-siRNA conjugates delivered into cerebrospinal fluid.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

<i>Staphylococcus aureus</i> inhibits the NLRP3 inflammasome in macrophages to varying degrees during early and late stages of infection.

Infection and immunity·2026
Same author

Osteomyelitis.

Nature reviews. Disease primers·2026
Same author

RANKL inhibits macrophage proinflammatory Toll-like receptor 2 and 4 signaling and impairs killing of intracellular bacteria.

ImmunoHorizons·2026
Same author

Erratum for Petronglo et al., "Context-Dependent Roles for Toll-Like Receptors 2 and 9 in the Pathogenesis of <i>Staphylococcus aureus</i> Osteomyelitis".

Infection and immunity·2026

Related Experiment Video

Updated: Nov 26, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.7K

Diflunisal-loaded poly(propylene sulfide) nanoparticles decrease S. aureus-mediated bone destruction during

Caleb A Ford1, Thomas J Spoonmore2, Mukesh K Gupta1

  • 1Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.

Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|December 10, 2020
PubMed
Summary
This summary is machine-generated.

Diflunisal, an anti-inflammatory drug, can treat bone infections. Nanoparticles successfully delivered diflunisal systemically to reduce Staphylococcus aureus-induced bone damage in osteomyelitis.

Keywords:
Staphylococcus aureusantivirulencedrug deliverynanoparticleosteomyelitis

More Related Videos

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.5K
Retroductal Nanoparticle Injection to the Murine Submandibular Gland
07:45

Retroductal Nanoparticle Injection to the Murine Submandibular Gland

Published on: May 3, 2018

10.5K

Related Experiment Videos

Last Updated: Nov 26, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.7K
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.5K
Retroductal Nanoparticle Injection to the Murine Submandibular Gland
07:45

Retroductal Nanoparticle Injection to the Murine Submandibular Gland

Published on: May 3, 2018

10.5K

Area of Science:

  • Infectious Diseases
  • Nanomedicine
  • Pharmacology

Background:

  • Osteomyelitis is a severe bone infection often caused by Staphylococcus aureus.
  • Staphylococcus aureus possesses virulence factors that exacerbate bone destruction and evade immune responses.
  • Previous local delivery of diflunisal reduced bone destruction but faced challenges with bacterial colonization of drug depots.

Purpose of the Study:

  • To develop an alternative drug delivery method for diflunisal in treating osteomyelitis.
  • To investigate nanoparticle-based parenteral delivery of diflunisal to circumvent local delivery complications.
  • To assess the efficacy of diflunisal-loaded nanoparticles in mitigating Staphylococcus aureus-mediated bone destruction.

Main Methods:

  • Utilized a murine model of staphylococcal osteomyelitis.
  • Employed poly(propylene sulfide) (PPS) nanoparticles for drug delivery.
  • Administered diflunisal-loaded PPS nanoparticles systemically.

Main Results:

  • Poly(propylene sulfide) nanoparticles effectively accumulated at the infectious site in the osteomyelitis model.
  • Systemic administration of diflunisal-loaded nanoparticles successfully delivered the drug to infected bone.
  • Diflunisal-loaded nanoparticles significantly reduced Staphylococcus aureus-mediated bone destruction.

Conclusions:

  • Parenteral nanoparticle-based delivery is a feasible strategy for diflunisal in treating osteomyelitis.
  • This approach overcomes limitations associated with local drug delivery for bone infections.
  • Systemic delivery of diflunisal via nanoparticles shows promise as an antivirulence therapy for osteomyelitis.